The Effect of Chromium Supplementation on Polycystic Ovary Syndrome in Adolescents

Journal of Pediatric and Adolescent Gynecology

Volumn 28, Issue 2, 2015, Pages 114-118

  Amr, Nermine ^a   Abdel Rahim, Hossam Eldin ^b  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b AL AZHAR UNIVERSITY   (Egypt)

Author keywords

Adolescents; Chromium; Polycystic ovary syndrome

Indexed keywords

CHROMIUM PICOLINATE; TESTOSTERONE; CHROMIUM;

ACNE; ADOLESCENT; ADOLESCENT DISEASE; AMENORRHEA; ARTICLE; BODY MASS; CLINICAL ARTICLE; COLORIMETRY; DIARRHEA; DRUG EFFECT; ECHOGRAPH; ECHOGRAPHY; FEMALE; HEADACHE; HIRSUTISM; HUMAN; INVESTIGATIVE PROCEDURES; MENSTRUAL IRREGULARITY; OBESITY; OLIGOMENORRHEA; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; SUPPLEMENTATION; TREATMENT OUTCOME; URTICARIA; VERTIGO; ACNE VULGARIS; BLOOD; DIETARY SUPPLEMENT; INSULIN RESISTANCE; MENSTRUATION DISORDER; POLYCYSTIC OVARY SYNDROME;

ACNE VULGARIS; ADOLESCENT; AMENORRHEA; BODY MASS INDEX; CHROMIUM; DIETARY SUPPLEMENTS; FEMALE; HIRSUTISM; HUMANS; INSULIN RESISTANCE; MENSTRUATION DISTURBANCES; POLYCYSTIC OVARY SYNDROME; TESTOSTERONE; TREATMENT OUTCOME;

EID: 84926392820     PISSN: 10833188     EISSN: 18734332     Source Type: Journal    
DOI: 10.1016/j.jpag.2014.05.005     Document Type: Article

References (55)

1. Azziz R., Woods K.S., Reyna R., et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004, 89:2745.
2. Azziz R., Carmina E., Dewailly D., et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009, 91:456. Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society.
3. Hickey M., Doherty D.A., Atkinson H., et al. Clinical, ultrasound and biochemical features of polycystic ovary syndrome in adolescents: implications for diagnosis. Hum Reprod 2011, 26:1469.
4. Esmaeilzadeh S., Delavar M.A., Amiri M., et al. Polycystic ovary syndrome in Iranian adolescents. Int J Adolesc Med Health 2014, 22:1.
5. Vilmann L.S., Thisted E., Baker J.L., et al. Development of obesity and polycystic ovary syndrome in adolescents. Horm Res Paediatr 2012, 78:269.
6. Rossi B., Sukalich S., Droz J., et al. Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome. J Clin Endocrinol Metab 2008, 93:4780.
7. Sir-Petermann T., Codner E., Pérez V., et al. Metabolic and reproductive features before and during puberty in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2009, 94:1923.
8. Prapas N., Karkanaki A., Prapas I., et al. Genetics of polycystic ovary syndrome. Hippokratia 2009, 13:216.
9. Allen H.F., Mazzoni C., Heptulla R.A., et al. Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. J Pediatr Endocrinol Metab 2005, 18:761.
10. Toscani M.K., Mario F.M., Radavelli-Bagatini S., et al. Insulin resistance is not strictly associated with energy intake or dietary macronutrient composition in women with polycystic ovary syndrome. Nutr Res 2011, 31:97.
11. Chakraborty P., Ghosh S., Goswami S.K., et al. Altered trace mineral milieu might play an aetiological role in the pathogenesis of polycystic ovary syndrome. Biol Trace Elem Res 2013, 152:9.
12. Lucidi R.S., Thyer A.C., Easton C.A., et al. Effect of chromium supplementation on insulin resistance and ovarian and menstrual cyclicity in women with polycystic ovary syndrome. Fertil Steril 2005, 84:1755.
13. Cefalu W.T., Hu F.B. Role of chromium in human health and in diabetes. Diabetes Care 2004, 11:2741.
14. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004, 81:19. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group.
15. Merino P.M., Codner E., Cassorla F. A rational approach to the diagnosis of polycystic ovarian syndrome during adolescence. Arq Bras Endocrinol Metabol 2011, 55:590.
16. Balen A.H., Laven J.S., Tan S.L., et al. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 2003, 9:505.
17. Ferriman D., Gallwey J.D. Clinical assessment of body hair growth in women. JClin Endocrinol Metab 1961, 21:1440.
18. Thiboutot D., Archer D.F., Lemay A., et al. A randomized, controlled trial of a low-dose contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for acne treatment. Fertil Steril 2001, 76:461.
19. Cole T.J., Freeman J.V., Preece M.A. Body mass index reference curves for the UK, 1990. Arch Dis Child 1995, 73:25.
20. Teede H., Deeks A., Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Medicine 2010, 8:41.
21. Vinaixa M., Rodriguez M.A., Samino S., et al. Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy. PLoS ONE 2011, 6:e29052.
22. Jing Z., Liang-Zhi X., Tai-Xiang W., et al. The effects of Diane-35 and metformin in treatment of polycystic ovary syndrome: an updated systematic review. Gynecol Endocrinol 2008, 24:590.
23. Sirmans S.M., Pate K.A. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol 2013, 6:1.
24. Habibzadeh F: Contraception in the Middle East. Available: Accessed February 4,2014. http://download.thelancet.com/flatcontentassets/pdfs/Sep12_MiddleEastEd.pdf?elsca1=010912%26elsca2=MIDDLEEADTED%26elsca3=segment.
25. Glueck C.J., Wang P., Fontaine R., et al. Metformin to restore menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). JAdolesc Health 2001, 29:160.
26. Tang T., Lord J.M., Norman R.J., et al. Insulin-sensitizing drugs (metformin, rosiglitazone, pioglitaazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 2012, (5):CD003053.
27. Badawi A., Elnashar A. Treatment options for polycystic ovary syndrome. Int J Womens Health 2011, 3:25.
28. Suksomboon N., Poolsup N., Yuwanakorn A. Systematic review and meta-analysis of the efficacy and safety of chromium supplementation in diabetes. J Clin Pharm Ther 2014, 39:292.
29. Ravina A., Slezak L., Mirsky N., et al. Reversal of corticosteroid-induced diabetes mellitus with supplemental chromium. Diabet Med 1999, 2:164.
30. Morris B.W., MacNeil S., Hardisty C.A., et al. Chromium homeostasis in patients with type II (NIDDM) diabetes. J Trace Elem Med Biol 1999, 13:57.
31. Morris B.W., Kouta S., Robinson R., et al. Chromium supplementation improves insulin resistance in patients with type 2 diabetes mellitus. Diabet Med 2000, 17:684.
32. Cefalu W.T., Wang Z.Q., Zhang X.H., et al. Oral chromium picolinate improves carbohydrate and lipid metabolism and enhances skeletal muscle Glut-4 translocation in obese, hyperinsulinemic (JCR-LA corpulent) rats. J Nutr 2002, 132:1107.
33. Gunton J.E., Cheung N.W., Hitchman R., et al. Chromium supplementation does not improve glucose tolerance, insulin sensitivity, or lipid profile: a randomized, placebo-controlled, double-blind trial of supplementation in subjects with impaired glucose tolerance. Diabetes Care 2005, 28:712.
34. Seif A.A. Chromium picolinate inhibits cholesterol-induced stimulation of platelet aggregation in hypercholesterolemic rats. Ir J Med Sci 2014, [Epub ahead of print].
35. Okada S., Tsukada H., Ohba H. Enhancement of nucleolar RNA synthesis by chromium(II1) in regenerating rat liver. J Inorg Biochem 1984, 21:113.
36. Al-Rasheed N.M., Attia H.A., Mohamed R.A., et al. Preventive effects of selenium yeast, chromium picolinate, zinc sulfate and their combination on oxidative stress, inflammation, impaired angiogenesis and atherogenesis in myocardial infarction in rats. J Pharm Pharm Sci 2013, 16:848.
37. Lydic M.L., McNurlan M., Bembo S., et al. Chromium picolinate improves insulin sensitivity in obese subjects with polycystic ovary syndrome. Fertil Steril 2006, 86:243.
38. Wang Z.Q., Cefalu W.T. Current concepts about chromium supplementation in type 2 diabetes and insulin resistance. Curr Diab Rep 2010, 10:145.
39. Balk E.M., Tatsioni A., Lichtenstein A., et al. Effect of chromium supplementation on glucose metabolism and lipids. A systematic review of randomized controlled trials. Diabetes Care 2007, 30:2154.
40. Anderson R.A., Cheng N., Bryden N.A., et al. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes 1997, 46:1786.
41. Abdollahi M., Farshohi A., Nikfar S., et al. Effect of chromium on glucose and lipid profiles in patients with type 2 diabetes; a meta-analysis review of randomized trials. J Pharm Pharm Sci 2013, 16:99.
42. Mastorakos G., Lambrinoudaki I., Creatsas G. Polycystic ovary syndrome in adolescents: current and future treatment options. Paediatr Drugs 2006, 8:311.
43. Orsino A., Van Eyk N., Hamilton J. Clinical features, investigations and management of adolescents with polycystic ovary syndrome. Paediatr Child Health 2005, 10:602.
44. Gjønnaess H. Ovarian electrocautery in the treatment of women with polycystic ovary syndrome (PCOS). Factors affecting the results. Acta Obstet Gynecol Scand 1994, 73:407.
45. Patel S.M., Nestler J.E. Fertility in polycystic ovary syndrome. Endocrinol Metab Clin North Am 2006, 35:137.
46. Anderson R.A. Effects of chromium on body composition and weight loss. Nutr Rev 1998, 56:266.
47. Hallmark M.A., Reynolds T.H., DeSouza C.A., et al. Effects of chromium and resistive training on muscle strength and body composition. Med Sci Sports Exerc 1996, 28:139.
48. Trent L.K., Thieding-Cancel D. Effects of chromium picolinate on body composition. J Sports Med Phys Fitness 1995, 35:273.
49. Clancy S.P., Clarkson P.M., DeCheke M.E., et al. Effects of chromium picolinate supplementation on body composition, strength, and urinary chromium loss in football players. Int J Sport Nutr 1994, 4:142.
50. Fauser B.C., Tarlatzis B.C., Reber R.W., et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012, 97:28.e25.
51. Calaf J., López E., Millet A., et al. Long-term efficacy and tolerability of flutamide combined with oral contraception in moderate to severe hirsutism: a 12-month, double-blind, parallel clinical trial. J Clin Endocrinol Metab 2007, 92:3446.
52. Slayden S.M., Moran C., Sams W.M., et al. Hyperandrogenemia in patients presenting with acne. Fertil Steril 2001, 75:889.
53. Norman R.J., Dewailly D., Legro R.S., et al. Polycystic ovary syndrome. Lancet 2007, 370:685.
54. Goodarzi M.O., Dumesic D.A., Chazenbalk G., et al. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol 2011, 7:219.
55. Amooee S., Parsanezhad M.E., Ravanbod Shirazi M., et al. Metformin versus chromium picolinate in clomiphene citrate-resistant patients with PCOs: A double-blind randomized clinical trial. Iran J Reprod Med 2013, 11:611.